Literature DB >> 27250868

A meta-analysis of extracorporeal shock wave therapy for Peyronie's disease.

L Gao1, S Qian1, Z Tang1, J Li1, J Yuan1.   

Abstract

The efficiency of extracorporeal shock wave therapy (ESWT) for Peyronie's disease (PD) has been controversial for a very long time. We aimed to evaluate the efficiency of ESWT for PD and provide possible evidence on the basis of a meta-analysis of existing comparative studies. All controlled studies, including randomized controlled trials (RCTs), cohort studies and case-control studies, that focused on the efficiency of ESWT for PD, were prospectively identified through comprehensive searches of PubMed, the Cochrane Library and Embase databases. We conducted a meta-analysis of these studies. Six studies including 443 patients were selected for the meta-analysis. Pooling data of these studies showed that ESWT could significantly increase the percentage of men with lessening of penile plaques (odds ratio (OR) 2.07, 95% confidence interval (CI) 1.11-3.85, P=0.02), relief of pain (OR 4.46, 95% CI 2.29-8.68, P<0.0001) and complete remission of pain (OR 5.86, 95% CI 2.66-12.92, P<0.0001). However, insignificant differences were found in improvement of penile curvature (OR 1.88, 95% CI 0.97-3.65, P=0.06) and sexual function (OR 2.22, 95% CI 0.69-7.11, P=0.18) between ESWT and placebo groups. Further, similar results were shown for sensitivity and publication bias analysis when only RCTs were included. However, sporadic complications caused by ESWT were reported, but no patient needed additional treatment aside from conservative observation. ESWT may be an effective and safe treatment for lessening of penile plaques and relieving pain for men with PD, but not for improving of penile curvature and sexual function.

Entities:  

Mesh:

Year:  2016        PMID: 27250868     DOI: 10.1038/ijir.2016.24

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  27 in total

1.  Extracorporal shock wave therapy in the treatment of Peyronie's disease. First results of a case-controlled approach.

Authors:  E W Hauck; B M Altinkilic; M Ludwig; G Lüdecke; I Schroeder-Printzen; C Arens; W Weidner
Journal:  Eur Urol       Date:  2000-12       Impact factor: 20.096

2.  Extracorporeal shockwave therapy for Peyronie's disease does not correct penile deformity.

Authors:  R T Strebel; S Suter; T Sautter; D Hauri
Journal:  Int J Impot Res       Date:  2004-10       Impact factor: 2.896

3.  Extracorporeal shockwave therapy for Peyronie's disease: an alternative treatment?

Authors:  Vassilis Poulakis; Konstantinos Skriapas; Rachelle de Vries; Wolfgang Dillenburg; Nikolaos Ferakis; Ulrich Witzsch; Michael Melekos; Edward Becht
Journal:  Asian J Androl       Date:  2006-05       Impact factor: 3.285

Review 4.  Mechanisms of Disease: new insights into the cellular and molecular pathology of Peyronie's disease.

Authors:  Nestor F Gonzalez-Cadavid; Jacob Rajfer
Journal:  Nat Clin Pract Urol       Date:  2005-06

5.  Smoking, diabetes, blood hypertension: possible etiologic role for Peyronie's disease? Analysis in 279 patients with a control group in Sicily.

Authors:  Carlo Pavone; Francesco D'Amato; Nino Dispensa; Federico Torretta; Carlo Magno
Journal:  Arch Ital Urol Androl       Date:  2015-03-31

6.  The prevalence of Peyronie's disease in diabetic patients with erectile dysfunction.

Authors:  M Arafa; H Eid; A El-Badry; K Ezz-Eldine; R Shamloul
Journal:  Int J Impot Res       Date:  2006-08-17       Impact factor: 2.896

7.  Extracorporeal shock wave therapy in the treatment of Peyronie's disease: long-term results.

Authors:  Ettore De Berardinis; Gian Maria Busetto; Gabriele Antonini; Riccardo Giovannone; Vincenzo Gentile
Journal:  Arch Ital Urol Androl       Date:  2010-06

8.  Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial.

Authors:  A Palmieri; C Imbimbo; M Creta; P Verze; F Fusco; V Mirone
Journal:  Int J Androl       Date:  2011-11-15

9.  [Possibility of using the piezoelectric lithotriptor in the treatment of severe cavernous fibrosis].

Authors:  C Bellorofonte; M Ruoppolo; M Tura; C Zaatar; P Tombolini; G F Menchini Fabris
Journal:  Arch Ital Urol Nefrol Androl       Date:  1989-12

10.  Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening.

Authors:  John P Mulhall; Steven D Creech; Stephen A Boorjian; Sam Ghaly; Edward D Kim; Ayham Moty; Rodney Davis; Wayne Hellstrom
Journal:  J Urol       Date:  2004-06       Impact factor: 7.450

View more
  8 in total

1.  Laser Therapy for Peyronie's Disease: A Randomized Control Double-Blind Pilot Study.

Authors:  Farzad Allameh; Mohammadreza Razzaghi; Seyed Mansoor Rayegani; Morteza Fallah-Karkan; Arash Ranjbar; Amirhosein Rahavian; Atefeh Javadi; Saleh Ghiasy; Zahra Razzaghi
Journal:  J Lasers Med Sci       Date:  2019-12-01

2.  A Critical Analysis of Reporting in Systematic Reviews and Meta-Analyses in the Peyronie's Disease Literature.

Authors:  Raevti Bole; Harrison Chase Gottlich; Matthew J Ziegelmann; Dillon Corrigan; Laurence A Levine; John P Mulhall; Petar Bajic
Journal:  J Sex Med       Date:  2022-02-15       Impact factor: 3.937

Review 3.  Short-term efficacy and safety of low-intensity extracorporeal shock wave therapy in erectile dysfunction: a systematic review and meta-analysis.

Authors:  Zi-Jun Zou; Liang-You Tang; Zhi-Hong Liu; Jia-Yu Liang; Ruo-Chen Zhang; Yu-Jie Wang; Yong-Quan Tang; Rui Gao; Yi-Ping Lu
Journal:  Int Braz J Urol       Date:  2017 Sep-Oct       Impact factor: 1.541

4.  Editorial Comment: Low-Intensity Shock Wave Therapy in Sexual Medicine-Clinical Recommendations.

Authors:  Rodrigo R Vieiralves
Journal:  Int Braz J Urol       Date:  2020 Jan-Feb       Impact factor: 1.541

5.  Peyronie's disease may negatively impact the sexual experience of a couple and female sexual function: a single center study.

Authors:  Ester Illiano; Francesco Trama; Vito Mancini; Antonio Ruffo; Giuseppe Romeo; Filippo Riccardo; Consuelo Fabi; Giuseppe Carrieri; Felice Crocetto; Fabrizio Iacono; Elisabetta Costantini
Journal:  Transl Androl Urol       Date:  2021-02

Review 6.  Nonsurgical Interventions for Peyronie's Disease: Update as of 2016.

Authors:  Gregory A Joice; Arthur L Burnett
Journal:  World J Mens Health       Date:  2016-08-23       Impact factor: 5.400

7.  Focused electromagnetic high-energetic extracorporeal shockwave (ESWT) reduces pain levels in the nodular state of Dupuytren's disease-a randomized controlled trial (DupuyShock).

Authors:  Karsten Knobloch; Marie Hellweg; Heiko Sorg; Tomas Nedelka
Journal:  Lasers Med Sci       Date:  2021-01-23       Impact factor: 3.161

8.  Low-intensity extracorporeal shock wave therapy for Peyronie's disease: a single-center experience.

Authors:  Maher Abdessater; William Akakpo; Anthony Kanbar; Jérome Parra; Thomas Seisen; Emmanuel Chartier-Kastler; Sarah J Drouin; Morgan Roupret
Journal:  Asian J Androl       Date:  2022 Jan-Feb       Impact factor: 3.285

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.